Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir/velpatasvir combination

Micallef, Sarah; Gauci, Julia; Gerada, Jurgen

doi:10.12968/hmed.2020.0047

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, most of those studies were case reports or case series, although the SVR12 was achieved in all patients. [103][104][105][106][107][108] Chromy et al…”

Section: Real-world Studiesmentioning

confidence: 99%

“…Limited real-world studies have demonstrated the effectiveness of DAAs for low-risk general patients with acute HCV infection. Furthermore, most of those studies were case reports or case series, although the SVR 12 was achieved in all patients [ 103 - 108 ]. Chromy et al [ 109 ] retrospectively assessed 38 PLWH with acute HCV infection treated with various DAA regimens.…”

Section: Treatment With Ifn-free Daasmentioning

confidence: 99%

See 1 more Smart Citation

Acute hepatitis C virus infection: clinical update and remaining challenges

Liu¹,

Kao²

2023

Clin Mol Hepatol

View full text Add to dashboard Cite

Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus are reported to be most susceptible to acute HCV infection. The diagnosis of acute HCV infection is particularly challenging in immunocompromised, reinfected, and superinfected patients due to difficulty in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid (RNA) from a previously negative antibody response. With an excellent treatment effect on chronic HCV infection, recently, clinical trials investigating the benefit of direct-acting antivirals (DAAs) treatment for acute HCV infection have been conducted. Based on the results of costeffectiveness analysis, DAAs should be initiated early in acute HCV infection prior to spontaneous viral clearance. Compared to the standard 8-12 week-course of DAAs for chronic HCV infection, DAAs treatment duration may be shortened to 6-8 weeks in acute HCV infection without compromising the efficacy. Standard DAA regimens provide comparable efficacy in treating HCV-reinfected patients and DAA-naïve ones. For cases contracting acute HCV infection from HCV-viremic liver transplant, a 12-week course of pangenotypic DAAs is suggested. While for cases contracting acute HCV infection from HCV-viremic non-liver solid organ transplants, a short course of prophylactic or pre-emptive DAAs is suggested. Currently, prophylactic HCV vaccines are unavailable. In addition to treatment scale-up for acute HCV infection, practice of universal precaution, harm reduction, safe sex, and vigilant surveillance after viral clearance remain critical in reducing HCV transmission.

show abstract

“…Furthermore, most of those studies were case reports or case series, although the SVR12 was achieved in all patients. [103][104][105][106][107][108] Chromy et al…”

Section: Real-world Studiesmentioning

confidence: 99%